(Q38845362)

6 September 2017

1 reference

title

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? (English)

1 reference

6 September 2017

0 references

1 reference

3

1 reference

6 September 2017

2

Gerardo Botti

1 reference

6 September 2017

Paolo Antonio Ascierto

8

object named as

Paolo A Ascierto

1 reference

6 September 2017

Ignacio Melero, MD-PhD

7

object named as

Ignacio Melero

1 reference

6 September 2017

Lucia Festino

1

1 reference

6 September 2017

Giuseppe V Masucci

4

1 reference

6 September 2017

Jason D Hipp

5

1 reference

6 September 2017

Christine E Horak

6

1 reference

6 September 2017

26 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

76

1 reference

6 September 2017

9

1 reference

6 September 2017

925-945

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0588-x

6 September 2017

0 references

cites work

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS40265-016-0588-X

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS40265-016-0588-X

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

How tolerogenic dendritic cells induce regulatory T cells

1 reference

12 December 2020

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

1 reference

12 December 2020

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

12 December 2020

Consensus nomenclature for CD8(+) T cell phenotypes in cancer

1 reference

12 December 2020

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

12 December 2020

Overall survival and PD-L1 expression in metastasized malignant melanoma

1 reference

12 December 2020

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

1 reference

12 December 2020

Immune surveillance of tumors

1 reference

12 December 2020

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 December 2020

T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

1 reference

12 December 2020

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

1 reference

12 December 2020

A link between PDL1 and T regulatory cells in fetomaternal tolerance

1 reference

12 December 2020

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

1 reference

12 December 2020

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

1 reference

12 December 2020

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 December 2020

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

12 December 2020

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 December 2020

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 December 2020

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

1 reference

12 December 2020

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

1 reference

12 December 2020

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

1 reference

12 December 2020

Innate and adaptive immune cells in the tumor microenvironment

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

12 December 2020

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

1 reference

12 December 2020

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

12 December 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 December 2020

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

12 December 2020

PD-1 and its ligands in tolerance and immunity

1 reference

12 December 2020

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

1 reference

12 December 2020

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

1 reference

12 December 2020

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

1 reference

12 December 2020

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

12 December 2020

Programmed death-1 pathway in cancer and autoimmunity.

1 reference

12 December 2020

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

12 December 2020

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 December 2020

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

12 December 2020

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

12 December 2020

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 December 2020

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 December 2020

10.1007/S40265-016-0588-X

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference